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Purpose: To evaluate the efficacy and safety of intravitreal bevacizumab for polypoidal choroidal 
vasculopathy (PCV).
Methods: In this retrospective interventional pilot study, 12 eyes of 11 patients with active PCV were treated 
with intravitreal bevacizumab (1.25 mg) alone or in combination with photodynamic therapy (PDT) depending 
on the informed patient’s choice. Intravitreal bevacizumab was repeated at 6‐week intervals until the 
regression of active lesion was detected on fluorescein angiography (FA) which was done on a regular 
basis, Indocyanine green angiography (ICGA) and optical coherence tomography (OCT) analyses.
Results: Intravitreal bevacizumab was given alone in 8 eyes (Group 1) and in combination with PDT in 4 
eyes (Group 2). Mean follow‐up duration was 17 weeks in group 1 and 15 weeks in group 2 after 
bevacizumab treatment. The mean number of bevacizumab injections was 2.2 in group 1 and 2.5 in group 
2. Mean BCVA improved from 20/63 to 20/40 in group 1 and 20/63 to 20/32 in group 2. Of all eyes, the 
BCVA improved by ≥2 lines in seven (58%) eyes and resolution of fluid and hemorrhages in clinical 
examination, an absence of leakage on repeat FAs, or resolved pigment epithelial detachment (PED) and/or 
subretinal fluid (SRF) on OCT exam was confirmed in 10 (83%) eyes. Partial or complete regression of the 
polypoidal vessels and interconnecting vessels was reported for most cases at the last follow‐up. No 
significant ocular or systemic side effects were observed in both groups.
Conclusions: Short‐term results indicate that intravitreal bevacizumab (1.25 mg) alone or in combination with 
PDT is well tolerated and associated with improvement in BCVA and reduced angiographic leakage in most 
patients. Further evaluation of intravitreal bevacizumab therapy for the treatment of PCV is warranted. 
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Polypoidal choroidal vasculopathy (PCV) is a choroidal 
vascular disease characterized by an inner choroidal vascular 
network ending in an aneurysmal bulge or outward projection 
visible clinically as a reddish orange, spheroid, polyp‐like 
structure.
1‐3
PCV can remain clinically asymptomatic in its quiescent 
form, with nonleaking asymptomatic polyps. Occasionally, 
PCV causes insidious visual loss owing to serosanguinous 
detachment of the retinal pigment epithelium and 
neurosensory retina affecting the macula, or causes acute and 
severe visual loss secondary to massive submacular or 
vitreous hemorrhage due to spontaneously ruptured vessels.
4,5 
Treatment for PCV is not yet well established. Asymptomatic 
PCV is recommended for observation and the polyps may 
resolve spontaneously over time.
5,6 Although various treatment 
modalities for PCV with exudative and hemorrhagic 
complications such as direct thermal laser photocoagulation, 
tissue plasminogen activator (t‐PA) injection with gas 
displacement, submacular surgery, and macular translocation 
surgery have been proposed, the beneficial effects are still in 
doubt owing to recurrence or poor long‐term results.
7‐11 
Recently, photodynamic therapy (PDT) has been proposed as 
a standard treatment modality with its favorable outcome, 
nevertheless its application has been found to be limited 
owing to difficulty in treating all wide spread multiple polyps 
and the possibility of subsequent massive submacular 
hemorrhage.
12‐14
Favorable results have been reported with intravitreal 
injection of bevacizumab (Avastin
®, Genentech, Inc. South 
San Francisco, CA) to treat choroidal neovascularization.
15‐18 SY Lee, et al, THE EFFECTS OF BEVACIZUMAB IN PCV  
93
Table 1. Clinical Data and Treatment Results in Patients with Polypoidal Choroidal Vasculopathy Treated by 
Intravitreal Bevacizumab (Group 1) 
PatientNo./
Gender/
Age (years)
Location Prior 
Tx Treatment*
 
BCVA
Pre**
 
BCVA
Final
Change
in lines
Duration
of F/U
†
(week)
Clinical and 
angiographic 
features at 
last F/U
OCT
features 
at last F/U
Additional 
event
1/M/66 Subfoveal P(‐36) A(0),A(6),A(12) 20/100 20/160 ‐21 7 D r y  a n d
quiescent
Resolved 
PED
2/M/80 Juxtafoveal A(0),A(6),A(12) 20/50 20/32 +2 13 Dry and 
quiescent
Reduced PED 
and SRF
3/M/63 Subfoveal A(0),A(6),A(12) 20/63 20/32 +3 17 Dry and 
quiescent Resolved SRF
4/M/63 Subfoveal P(‐6), 
T/G
A(0),A(6) 20/200 20/320 ‐21 2 D r y  a n d  
scarring
Resolved PED 
and RPE 
scarring
Massive 
subretinal 
hemorrhage 
after PDT
5/M/57 Extrafoveal A(0) 20/25 20/25 0 22 Dry and 
quiescent Resolved PED
6/M/58 Juxtafoveal A(0),A(6) 20/100 20/32 +5 27 Dry and 
quiescent
Resolved PED 
and SRF
7/M/58 Extrafoveal A(0) 20/40 20/40 0 20 Dry and 
quiescent Resolved SRF
8/M/62 Subfoveal P(‐16) A(0),A(6),A(12) 20/50 20/32 +2 13 Dry and 
quiescent Resolved PED
M=male; F=female; Tx=treatment; F/U=follow‐up; P=photodynamic therapy, PDT; T/G=t‐PA with gas injection; L=focal 
laser photocoagulation, A=intravitreal bevacizumab; BCVA=best corrected visual acuity; PED=pigment epithelial detachment; 
SRF=subretinal fluid;RPE=retinal pigment epithelium.
* Treatment (time, weeks); ** BCVA before intravitreal bevacizumab; 
† follow‐up duration after intravitreal bevacizumab 
injection; 
‡ Localized bleeding at 6 weeks after PDT plus intravitreal bevacizumab. 
Although the pathogenesis of PCV is still not fully 
understood, it has been suggested that vascular endothelial 
growth factor (VEGF) may have a similar role in PCV as 
it does in choroidal neovascularization (CNV) owing to 
marked increases in VEGF concentration in aqueous humor 
and histologic examination in active PCV eyes.
19,20 The aim 
of the present study was to determine the efficacy and safety 
of intravitreal bevacizumab, alone or in combination with 
PDT, for the treatment of PCV. 
Materials and Methods
The retrospective interventional case series study included 
medical records of 12 eyes of 11 patients with symptomatic 
PCV who were either newly diagnosed or failed in previous 
treatment and treated PCV at Asan Medical Center, Seoul, 
Korea, from January 2006 to October 2006. The study was 
approved by the Institutional Review Board at the Asan 
Medical Center and informed consent was obtained from all 
patients. Patients with new or recurrent subretinal pigment 
epithelial orange‐red vascular lesions associated with 
exudative changes were included. To confirm the diagnosis 
of symptomatic PCV, all patients underwent fluorescein 
angiography (FA), indocyanine green angiography (ICGA), 
and optical coherence tomography (OCT) analyses. All 
patients also underwent a comprehensive ocular examination, 
including best‐corrected visual acuity (BCVA), slit‐lamp 
biomicroscopy with intraocular pressure measurement and 
indirect ophthalmoscopy.
Patients received either an intravitreal injection of 
bevacizumab alone (Group 1) or an intravitreal injection of 
bevacizumab combined with PDT on the same day (Group 
2) according to informed patient’s choice. For intravitreal 
injection, 1.25 mg of bevacizumab was given using a 30‐
gauage needle after topical anesthesia. For combination 
therapy, PDT was performed to cover the entire lesion of 
symptomatic PCV lesions in a standard manner and the 
1.25 mg intravitreal bevacizumab injection was then 
administered.
Follow‐up evaluations were made at 1 week, 6 weeks and 
then every 2–3 months after treatment. BCVA, funduscopic 
exam, and OCT tests were performed at every visit, and 
FA/ICGA was assessed at the ~3 month visit or earlier if 
necessary. FA/ICGA findings were reviewed to confirm the 
regression of active PCV, and visual acuity and tomographic 
findings were recorded to assess the efficacy of the treatment. 
Side effects related to the procedure were also evaluated.
Results
The patient characteristics and clinical data of group 1 and 
group 2 are listed in Table 1 and Table 2. The 11 patients 
(ten men and one woman) were aged 45–80 years (mean 
63±7 years in group 1 and 53±7 years in group 2). Cases 
1 and 8 in group 1 and case 9 in group 2 received prior PDT 
(9, 4, and 22 months before treatment of bevacizumab, Kor J Ophthalmol Vol.22, No.2, 2008
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Table 2. Clinical Data and Treatment Results in Patients with Polypoidal Choroidal Vasculopathy Treated by 
Intravitreal Bevacizumab combined with photodynamic therapy (Group 2) 
PatientNo./
Gender/
Age (years)
Location Prior 
Tx
Treatment* BCVA
Pre**
BCVA
Final
Change
in lines
Duration
of F/U
†
(week)
Clinical and 
angiographic 
features 
at last F/U
OCT
features 
at last F/U
Additional 
event
9/F/51 Subfoveal P(‐88) P+A(0),A(6),A(12) 20/250 20/250 0 13 Persistent 
serous PED
Persistent 
serous PED
Localized 
bleeding(6)
‡ 
10/M/57 Subfoveal P+A(0),A(6),A(12) 20/63 20/32 +3 13 Persistent 
serous PED
Persistent 
serous PED
11/M/45 Extrafoveal T/G P+A(0),L(4) 20/100 20/25 +6 22 Dry and 
quiescent
Resolved PED 
and SRF
12/M/62 Subfoveal P+A(0),A(6),A(12) 20/32 20/20 +2 13 Quiescent Resolved PED
M=male; F=female; Tx=treatment; F/U=follow‐up; P=photodynamic therapy, PDT; T/G=t‐PA with gas injection; 
A=intravitreal bevacizumab; BCVA=best corrected visual acuity; PED=pigment epithelial detachment; SRF=subretinal 
fluid;RPE=retinal pigment epithelium.
* Treatment (time, weeks); ** BCVA before intravitreal bevacizumab; 
† follow‐up duration after intravitreal bevacizumab 
injection; 
‡ Localized bleeding at 6 weeks after PDT plus intravitreal bevacizumab. 
respectively). Case 11 in group 2 had received prior gas 
tamponade with t‐PA due to massive submacular hemorrhage 
at presentation. Case 4 had previously received gas 
tamponade with t‐PA due to massive submacular hemorrhage 
followed by prior PDT. All patients who had received prior 
treatment switched treatment to intravitreal injection of 
bevacizumab with/without combined PDT owing to persistent 
or recurrent PCV. All patients except cases 5, 7 and 11 
received repeated intravitreal bevacizumab at 6 week intervals 
owing to persistent subretinal fluid, as shown by OCT 
analysis, or leakage, as shown by FA/ICGA analysis. 
Intravitreal bevacizumab was well tolerated in all patients. 
There were no procedure‐related complications in any of the 
patients.
Mean follow‐up duration was 17 weeks (range, 12-27) in 
group 1 and 15 weeks (range, 13-22) in group 2. The mean 
number of intravitreal bevacizumab injections was 2.2 in 
group 1 and 2.5 in group 2. Mean BCVA improved in both 
groups from 20/63 to 20/40 in group 1 and 20/63 to 20/32 
in group 2. Of all eyes, BCVA improved by ≥2 lines in 
seven (58%) eyes, and there was a moderate gain in vision 
in four (33%) of these eyes (BCVA improved by ≥3 lines). 
Three (25%) eyes had stable vision, with BCVA at the last 
follow‐up being within 1 line of the initial BCVA level. 
Resolution of fluid and hemorrhages in clinical examination, 
and absence of leakage on repeat FAs or resolved pigment 
epithelial detachment (PED) and/or subretinal fluid (SRF) on 
OCT examinations could be seen in 10 (83%) eyes. 
Regression of the polypoidal vessels and interconnecting 
vessels were seen in most cases at the last follow‐up.
Case Report (Cases 3 and 4)
A 63‐year‐old man was referred to our clinic with a 5 
month history of reduced visual acuity in the right eye. At 
the first visit, his visual acuity was 20/63 in the right eye 
and 20/20 in the left eye. Based on the findings in FA and 
ICGA, he was diagnosed as having PCV in his right eye and 
was treated with PDT covering whole active lesions. Four 
weeks after PDT, funduscopic examination of the right eye 
revealed extensive subretinal hemorrhage with a reduced 
visual acuity of 20/320. The right eye with massive subretinal 
hemorrhage was treated with intravitreal t‐PA (50 µg) and 0.3 
ml of 100% C3F8. Postoperative prone positioning was 
maintained for 72 hours. Two weeks after administration of 
t‐PA injection and gas, funduscopic examination of the right 
eye showed dispersed and reduced subretinal hemorrhage 
(Fig. 1). At one month follow up, he complained a decreased 
vision to 20/50 in his untreated, left eye. The OCT 
examination demonstrated subfoveal serous elevation and 
FA/ICGA confirmed new active PCV in his left eye (Fig. 2). 
Both eyes were treated with an intravitreal injection of 1.25 
mg bevacizumab, two injections in the right eye and three 
injections in the left eye, at 6 week intervals. The final visual 
acuity was 20/320 in the right eye with fibrovascular scarring 
and 20/32 in the left eye with minimal subfoveal serous 
elevation.
Discussion
Polypoidal choroidal vasculopathy (PCV) was first 
described by Yannuzzi et al.
1  and is characterized by an 
abnormal vascular network of choroidal vessels with polyp‐
like dilations at the terminals of the branches. It is unclear 
whether PCV represents abnormal vessels from the choroidal 
circulation or is a variant of CNV. However, it is generally 
considered distinct from CNV of age‐related macular 
degeneration (AMD) for several reasons. First, PCV mainly 
affects Asians and pigmented individuals and is associated 
with an earlier onset and a relatively benign clinical course.1 
Second, a few histopathologic studies have revealed that, 
unlike CNV which is located mainly under the Bruch’s 
membrane, polypoidal lesions and a branching vascular 
network are observed inside the Bruch’s membrane in cases SY Lee, et al, THE EFFECTS OF BEVACIZUMAB IN PCV  
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Fig. 1. Case 4, with exudative maculopathy in the right eye. (A) Fundus photograph showing subretinal blood and subretinal serous 
detachment. (B) Midphase fluorescein angiogram (FA) showing an irregular hyperfluorescent area corresponding to the interconnecting 
vascular network (arrow). (C) Fundus photograph 4 weeks after photodynamic therapy (PDT) showing a massive subretinal 
hemorrhage, including the posterior pole. (D) Fundus photograph after two intravitreal bevacizumab injections followed by an 
intravitreal injection of tissue plasminogen activator (t‐PA) and 100% C3F8 (0.3 ml), showing chorioretinal scarring. 
of PCV.
11 Finally, although eyes affected with PCV have 
several retinal features in common with CNV of AMD, they 
also have some unique features such as a large (greater than 
4‐disc area) serosanguinous retinopathy, orange polyp‐like 
structures, an absence of macular drusen, and multiple lesions 
scattered throughout the posterior pole including the 
peripapillary region.
1
Since the role of VEGF in the pathogenesis of CNV was 
established, several studies have reported on the efficacy of 
anti‐VEGF therapy for the treatment of AMD‐related CNV.
15‐
17 An earlier study found that pegaptanib (OSI/Eyetech, 
Melville, NY) slowed the rate of visual loss, and a more 
recent, well‐controlled study demonstrated a marked 
improvement in visual acuity following ranibizumab 
(Genentech, South San Francisco, CA) treatment of exudat 
ANB AMD patients.
22,23 Although bevacizumab (Genetech) 
may have a lower affinity for VEGF than ranibizumab owing 
to structural differences, it has been reported to be as 
efficacious as ranibizumab in the treatment of CNV 
secondary to AMD or pathologic myopia by several 
investigators.
15‐18
While the present study has a limitation with its 
retrospective design, non‐randomized treatment groups, a 
small series of patients, and short follow‐up time, our results 
as a pilot study demonstrate the benefits of intravitreal 
injection of bevacizumab, either as monotherapy or in 
combination with PDT, for the treatment of active PCV. This 
is not surprising considering previous reports demonstrating 
the role of VEGF in PCV.
19,20
Although PDT is often considered a standard treatment 
modality for PCV owing to a high regression rate and 
favorable functional outcome, it is associated with several 
disadvantages.
12,13 First, PCV often presents as multiple, 
widely distributed lesions, so it might be difficult to treat all Kor J Ophthalmol Vol.22, No.2, 2008
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Fig. 2. Case 3, left eye, the fellow eye of the case 4 patient (Fig. 1). (A) Midphase indocyanine green angiogram (ICGA), showing 
multiple polypoidal dilations of choroidal vessels and an interconnecting network. (B) Optical coherence tomograph (OCT) showing 
subfoveal serous elevation and a polypoidal lesion (arrow head). (C) Midphase ICGA showing reduced polypoidal lesion and 
interconnecting vessels. (D) OCT after three intravitreal bevacizumab injections, showing reduced subretinal fluid and a polypoidal 
lesion re‐attached to the Bruch’s membrane and choroids (arrow head). 
lesions, including multiple polyps and interconnecting vessels, 
with a single beam of PDT. Treatment of leaking polypoidal 
dilations only without treating the entire vascular complex 
can result in persistence or worsening of exudation.
24,25 
Second, it can be difficult to treat nodules in the peripapillary 
area with a round PDT beam.
26 Third, features commonly 
associated with PCV such as a large PED or a large 
submacular hemorrhage are not usually amenable to PDT 
treatment.
27,28 Fourth, PCV tends to recur repeatedly so 
multiple PDT treatments are often necessary, which can 
increase the risk of long‐term choroidal atrophy.
29 Finally, 
cases of massive subretinal/suprachoroidal hemorrhage, as in 
case 4 in this study, have been reported soon after PDT.
14,30,31 
Although a direct causal association has not been proven, this 
devastating complication usually results in irreversible visual 
loss so the risk should be avoided whenever possible.
Although bevacizumab is recommended as adjuvant 
therapy in combination with PDT for advanced cases that 
require prompt closure of an abnormal choroidal neovascular 
complex (Fig. 4), our results indicate that bevacizumab alone 
may now be considered a primary treatment for early, milder 
cases, which often occur in the other eye of a patient with 
an already badly affected eye (Fig. 1, 2). The bilateral 
example (cases 3 and 4) presented in the case report are 
examples of a particularly serious complication of PDT, 
which could be avoided by treatment with bevacizumab alone 
in the patient’s other eye. Longer follow‐up is necessary to 
determine whether repeat bevacizumab injections alone are 
sufficient to induce permanent regression of PCV, or whether 
combination therapy with PDT is required.
As the use of intravitreal triamcinolone as an adjunct to 
PDT has been shown to improve the visual outcome by 
downregulated expression of inflammatory mediators, and 
possibly VEGF, after PDT, direct inhibition of VEGF by 
bevacizumab in combination with PDT may provide a 
beneficial synergistic effect.
32 In addition, direct VEGF 
inhibition with combination treatment would not only reduce 
the potential for neovascularization, but would also reduce 
retinal edema owing to laser burn.
This study has several limitations, including retrospective 
design, non‐randomized treatment groups, a small series of 
patients, and short follow‐up time. However, rapid SY Lee, et al, THE EFFECTS OF BEVACIZUMAB IN PCV  
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Fig. 3. Case 8 with persistent active polypoidal choroidal vasculopathy (PCV) 4 months after photodynamic therapy (PDT). (A) 
Fundus photograph showing dense subretinal hemorrhages and serous subretinal detachment. (B) Midphase fluorescein angiogram 
(FA) showing hypofluorescence corresponding to a subretinal hemorrhage and multiple dot‐shaped hyperfluorescent lesions. (C) 
Midphase indocyanine green angiogram (ICGA) showing multiple polypoidal dilations of choroidal vessels and an interconnecting 
vascular network. (D) Fundus photograph after three intravitreal bevacizumab injections, showing resolved subretinal hemorrhages and 
serous subretinal detachment. (E) Midphase FA after three intravitreal bevacizumab injections, showing only the retinal pigment 
epithelium (RPE) window defect without angiographic leakage in late phase (not shown). (F) Midphase ICGA after three intravitreal 
bevacizumab injections, showing regression of the polyps and an interconnecting vascular network. 
improvement in vision as well as no significant complications 
after intravitreal bevacizumab treatment are encouraging, and 
may indicate that intravitreal bevacizumab should be 
considered a new treatment for active symptomatic PCV.
In conclusion, our results indicate that intravitreal 
bevacizumab treatment, either alone or in combination with 
PDT, may be a promising approach for treating active, 
symptomatic PCV. Further investigations including a 
large, controlled trial, are necessary to determine the 
efficacy.Kor J Ophthalmol Vol.22, No.2, 2008
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Fig. 4. Case 12 (A) Fundus photograph showing some hemorrhages, subretinal serous detachment, and subretinal exudates. (B) 
Optical coherence tomograph (OCT) showing serous pigment epithelial detachment (PED). (C) Midphase fluorescein angiogram (FA) 
showing hyperfluorescence with serous PED and round, multiple isolated hyperfluorescence lesions and surrounding irregular 
hyperfluorescence. (D) Midphase indocyanine green angiogram (ICGA) showing multiple polypoidal dilation of the choroidal vessels 
and interconnecting network. (E) Fundus photograph after three intravitreal bevacizumab injections and one round of photodynamic 
therapy (PDT), showing reduced hemorrhages and subretinal serous elevation. (F) OCT after three intravitreal bevacizumab injections 
and one round of PDT, showing resolved serous PED. (G) Midphase fluorescein angiogram (FA) after three intravitreal bevacizumab 
injections and one round of PDT, showing reduced hyperfluorescence and reduced subretinal fluid. (H) Midphase ICGA after three 
intravitreal bevacizumab injections and one round of PDT, showing resolved polypoidal lesion and interconnecting vessels.SY Lee, et al, THE EFFECTS OF BEVACIZUMAB IN PCV  
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